Smoking cessation pharmacogenetics: analysis of varenicline and bupropion in placebo-controlled clinical trials.

ABSTRACT: Despite effective therapies for smoking cessation, most smokers find quitting difficult and most successful quitters relapse. Considerable evidence supports a genetic risk for nicotine dependence; however, less is known about the pharmacogenetics of smoking cessation. In the first pharmacogenetic investigation of the efficacy of varenicline and bupropion, we examined whether genes important in the pharmacodynamics and pharmacokinetics of these drugs and nicotine predict medication efficacy and adverse events. Subjects participated in randomized, double-blind, placebo-controlled smoking cessation clinical trials, comparing varenicline, a nicotinic acetylcholine receptor (nAChR) partial agonist, with bupropion, a norepinephrine/dopamine reuptake inhibitor, and placebo. Primary analysis inclu

SUBMITTER: King DP 

PROVIDER: S-EPMC3260990 | biostudies-literature | 2012 Feb

REPOSITORIES: biostudies-literature